Lower Dose of Afatinib Shows Promising Clinical Efficacy in Patients with NSCLC and EGFR Mutation

2020 Year in Review - Non–Small-Cell Lung Cancer - Lung Cancer

Patients treated with afatinib for EGFR-mutated (EGFRm) non–small-cell lung cancer (NSCLC) often require treatment modifications because of drug toxicities. This study aimed to evaluate the safety and efficacy of a lower dosage of afatinib in patients with EGFRm NSCLC.

The trial to assess a lower dose of afatinib was a multicenter, single-arm, open-label phase 2 study. A 20-mg daily dose of afatinib was given to treatment-naïve patients with advanced NSCLC and common EGFR mutations. The dosage of afatinib was maintained unless tumor growth occurred. Progression-free survival (PFS) was monitored as a primary end point, with a threshold median PFS of 9.2 months and an expected median PFS of 13.8 months.

Fifty-three patients from 21 institutions throughout Japan were enrolled in the trial between March 2017 and September 2018. Of the patients, 28 were women and the median age was 70 years (range, 37-85 years). The most common EGFR mutations included in the study were exon 19 deletion (56.6%) and L858R point mutation (43.4%). Most patients enrolled in the study had a performance status of 0 or 1 (86.8%).

The median follow-up was 20.8 months as of the March 2020 cutoff date. The study results included a median PFS of 12.6 months (95% confidence interval [CI], 9.7-14.3), a median time to treatment failure of 18.6 months (95% CI, 16.0-21.2), and overall survival not reached. The objective response rate was 66.6% (95% CI, 51.7-78.5), and the disease control rate was 92.5% (95% CI, 81.8-97.9). Twelve (22.6%) patients had a grade ≥3 adverse event, with 4 (7.5%) of the patients having diarrhea. This percentage of patients with diarrhea was lower than seen in phase 3 trials in which patients were receiving afatinib 40 mg daily. Eight patients from a group of 19 had an EGFR T790M resistance mutation. No correlation was found between afatinib plasma concentrations after 9 days and clinical outcomes or adverse events.

The authors concluded that, based on the study results, a low dose of afatinib should be considered as a possible standard therapy when treating patients with EGFRm NSCLC.

Reference
Noro R, et al. ESMO 2020. Abstract 1365P.

Related Items
Antibody–Drug Conjugate Shows Promising Activity in Patients with Advanced or Metastatic EGFR Mutation–Positive NSCLC
Patricia Stewart
TOP - January 2022 Vol 15, No 1 – Online Only published on January 20, 2022 in Lung Cancer
Amivantamab plus Lazertinib Combo Improves Response in Osimertinib-Resistant EGFR-Positive NSCLC
Patricia Stewart
TOP - November 2021 Vol 14, No 7 published on November 10, 2021 in Lung Cancer
Sotorasib Shows Encouraging Activity in Patients with NSCLC and KRAS p.G12C Mutation
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC
Patricia Stewart
TOP - September 2021 Vol 14, No 5 published on September 7, 2021 in Lung Cancer
Educating NSCLC Patients on Adverse Event Management
Kammi Fox-Kay, MSN, RN, AOCNS, ONN-CG(T), Cathy Simmons, RN, BSN, ONN-CG(T), Lauren Welch, MSN, NP-C, AOCNP
Videos published on July 8, 2021 in Interview with the Innovators, Lung Cancer, Adverse Events
Addressing Lung Cancer Screening Disparities in LGBT Populations
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Analysis Identifies EGFR as Most Common Mutation in Women with Lung Cancer and No Smoking History
William Ackerman
TOP - May 2021 Vol 14, No 3 published on May 14, 2021 in Lung Cancer
Cemiplimab Potential New Treatment Option for Patients with Advanced NSCLC and PD-L1 ≥50%
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
“Astonishing Results” Seen with First-Line Lorlatinib for the Treatment of ALK-Positive NSCLC
Patricia Stewart
TOP - January 2021 Vol 14, No 1 published on February 9, 2021 in Lung Cancer
Patients with BRAF V600E–Mutant NSCLC Show Improved Overall Survival with Dabrafenib + Trametinib Combination
2020 Year in Review - Non–Small-Cell Lung Cancer published on January 29, 2021 in Lung Cancer
Last modified: July 22, 2021